Ensysce Biosciences Inc - Asset Resilience Ratio
Ensysce Biosciences Inc (ENSC) has an Asset Resilience Ratio of 57.84% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ENSC capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2022)
This chart shows how Ensysce Biosciences Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Ensysce Biosciences Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ensysce Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ensysce Biosciences Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $4.31 Million | 57.84% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $4.31 Million | 57.84% |
Asset Resilience Insights
- Very High Liquidity: Ensysce Biosciences Inc maintains exceptional liquid asset reserves at 57.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Ensysce Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Ensysce Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Ensysce Biosciences Inc (2017–2022)
The table below shows the annual Asset Resilience Ratio data for Ensysce Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 53.49% | $3.15 Million | $5.89 Million | -21.22pp |
| 2021-12-31 | 74.71% | $12.26 Million | $16.42 Million | -24.68pp |
| 2019-12-31 | 99.39% | $195.31 Million | $196.51 Million | +0.32pp |
| 2018-12-31 | 99.06% | $202.92 Million | $204.83 Million | +0.20pp |
| 2017-12-31 | 98.86% | $200.12 Million | $202.43 Million | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more